- Browse by Author
Browsing by Author "Nguyen, Dana"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item A pathway linking pulse pressure to dementia in adults with Down syndrome(Oxford University Press, 2024-05-09) Rizvi, Batool; Lao, Patrick J.; Sathishkumar, Mithra; Taylor, Lisa; Queder, Nazek; McMillan, Liv; Edwards, Natalie C.; Keator, David B.; Doran, Eric; Hom, Christy; Nguyen, Dana; Rosas, H. Diana; Lai, Florence; Schupf, Nicole; Gutierrez, Jose; Silverman, Wayne; Lott, Ira T.; Mapstone, Mark; Wilcock, Donna M.; Head, Elizabeth; Yassa, Michael A.; Brickman, Adam M.; Neurology, School of MedicineAdults with Down syndrome are less likely to have hypertension than neurotypical adults. However, whether blood pressure measures are associated with brain health and clinical outcomes in this population has not been studied in detail. Here, we assessed whether pulse pressure is associated with markers of cerebrovascular disease and is linked to a diagnosis of dementia in adults with Down syndrome via structural imaging markers of cerebrovascular disease and atrophy. The study included participants with Down syndrome from the Alzheimer’s Disease - Down Syndrome study (n = 195, age = 50.6 ± 7.2 years, 44% women, 18% diagnosed with dementia). Higher pulse pressure was associated with greater global, parietal and occipital white matter hyperintensity volume but not with enlarged perivascular spaces, microbleeds or infarcts. Using a structural equation model, we found that pulse pressure was associated with greater white matter hyperintensity volume, which in turn was related to increased neurodegeneration, and subsequent dementia diagnosis. Pulse pressure is an important determinant of brain health and clinical outcomes in individuals with Down syndrome despite the low likelihood of frank hypertension.Item Joint-label fusion brain atlases for dementia research in Down syndrome(Wiley, 2022-05-25) Queder, Nazek; Phelan, Michael J.; Taylor, Lisa; Tustison, Nicholas; Doran, Eric; Hom, Christy; Nguyen, Dana; Lai, Florence; Pulsifer, Margaret; Price, Julie; Kreisl, William C.; Rosas, Herminia D.; Krinsky-McHale, Sharon; Brickman, Adam M.; Yassa, Michael A.; Schupf, Nicole; Silverman, Wayne; Lott, Ira T.; Head, Elizabeth; Mapstone, Mark; Keator, David B.; Alzheimer’s Biomarkers Consortium; Neurology, School of MedicineResearch suggests a link between Alzheimer's Disease in Down Syndrome (DS) and the overproduction of amyloid plaques. Using Positron Emission Tomography (PET) we can assess the in-vivo regional amyloid load using several available ligands. To measure amyloid distributions in specific brain regions, a brain atlas is used. A popular method of creating a brain atlas is to segment a participant's structural Magnetic Resonance Imaging (MRI) scan. Acquiring an MRI is often challenging in intellectually-imparied populations because of contraindications or data exclusion due to significant motion artifacts or incomplete sequences related to general discomfort. When an MRI cannot be acquired, it is typically replaced with a standardized brain atlas derived from neurotypical populations (i.e. healthy individuals without DS) which may be inappropriate for use in DS. In this project, we create a series of disease and diagnosis-specific (cognitively stable (CS-DS), mild cognitive impairment (MCI-DS), and dementia (DEM-DS)) probabilistic group atlases of participants with DS and evaluate their accuracy of quantifying regional amyloid load compared to the individually-based MRI segmentations. Further, we compare the diagnostic-specific atlases with a probabilistic atlas constructed from similar-aged cognitively-stable neurotypical participants. We hypothesized that regional PET signals will best match the individually-based MRI segmentations by using DS group atlases that aligns with a participant's disorder and disease status (e.g. DS and MCI-DS). Our results vary by brain region but generally show that using a disorder-specific atlas in DS better matches the individually-based MRI segmentations than using an atlas constructed from cognitively-stable neurotypical participants. We found no additional benefit of using diagnose-specific atlases matching disease status. All atlases are made publicly available for the research community.